Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Testosterone Replacement Therapy Guidelines

Introduction to Testosterone Replacement Therapy

  • Testosterone gel is recommended as the initial treatment for testosterone replacement therapy over injections due to more stable serum testosterone levels and lower risk of cardiovascular events and erythrocytosis 1

Comparison of Formulations

  • Testosterone gel provides more stable day-to-day testosterone levels without the peaks and valleys seen with injections 1
  • Testosterone gel is available as 1% and 1.62% formulations with typical dosing of 50-100 mg/day 2
  • Testosterone injections are available as testosterone cypionate or enanthate at 100-200 mg every 2 weeks or 50 mg weekly 2

Safety Considerations

  • The FDA required labeling changes in 2015 to inform about possible increased risk of heart attack and stroke with testosterone preparations 1
  • Evidence suggests testosterone injections are associated with greater risk of cardiovascular events, hospitalizations, and deaths compared to gels 1, 2
  • Injections are associated with significantly higher risk of erythrocytosis than topical preparations 3, 4
  • Erythrocytosis with injections is associated with supraphysiologic levels of bioavailable testosterone 3

Monitoring Recommendations

  • Monitor testosterone levels 2-3 months after treatment initiation and after any dose change 1
  • Once stable levels are confirmed, monitoring every 6-12 months is typically sufficient 1
  • Monitor hematocrit/hemoglobin and PSA levels regularly 5
  • For injections: measure testosterone levels midway between injections, targeting mid-normal values 1
  • For gels: levels can be measured at any time, understanding that peak values occur 6-8 hours after application 1

Clinical Decision Algorithm

  • Best for patients concerned about stable hormone levels and minimizing cardiovascular risk 1, 2
  • Consider if patient has history of or risk factors for cardiovascular disease 1
  • Weekly rather than biweekly injections if using injectable form provides more stable serum testosterone levels and reduces time spent in supratherapeutic and subtherapeutic ranges 1, 5

Common Pitfalls and Caveats

  • Erythrocytosis risk with testosterone therapy requires regular monitoring of hematocrit, especially with injections 3, 4
  • Both formulations can cause testicular atrophy and reduced fertility during therapy 5

REFERENCES